← Leaderboards
Mohamed K Khan
University Of Michigan At Ann Arbor
$1,881,704
Attributed
$1,881,704
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $274.2K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,881,704 · 2
By mechanism
R01$1,336,053 · 1
R21$545,651 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Ruma V Banerjee$24,139,300
- John D. Meeker$22,847,279
- Ursula H Jakob$17,756,858
- Yuqing E Chen$44,993,151
- Jose Arturo Bauermeister$13,049,205
Others in their field
Top investigators on “Copper”
- Svetlana Lutsenko · Oregon Health And Science University$18,045,733
- Kenneth D. Karlin · Johns Hopkins University$16,339,237
- Stephen L Buchwald · Massachusetts Institute Of Technology$15,093,202
- Ninian J Blackburn · Oregon Graduate Institute Science &Tech$14,898,278
- Michael J Petris · University Of Missouri-Columbia$14,851,498
- Edward I Solomon · Stanford University$13,845,825
Research focus
CopperGoldAutoradiographyAngiogenesis InhibitorsAntineoplasticsBiomarkerAngiogenesisBinding (Molecular Function)AntibodiesBiodistributionBioimaging /Biomedical ImagingBiological ModelsClassChargeBaseAnimalsClinical ResearchClinical Trial Phase ICombination Cancer TherapyComputed Axial Tomography3-DimensionalDailyDesignDetection
Grant awards (7)
Imaging Nanocomposites Targeting Tumor Microvasculature$259,975
R01 · FY2008 · CA · contact PI
Imaging Nanocomposites Targeting Tumor Microvasculature$259,975
R01 · FY2007 · CA · contact PI
Imaging Nanocomposites Targeting Tumor Microvasculature$267,739
R01 · FY2006 · CA · contact PI
Imaging Nanocomposites Targeting Tumor Microvasculature$274,182
R01 · FY2005 · CA
Anti-angiogenic Tetrathiomolybdate +XRT in NSCLC-Phase 1$304,023
R21 · FY2004 · CA
Imaging Nanocomposites Targeting Tumor Microvasculature$274,182
R01 · FY2004 · CA
Anti-angiogenic Tetrathiomolybdate +XRT in NSCLC-Phase 1$241,628
R21 · FY2003 · CA